H. Lundbeck A/s Class A · OMXCOP:HLUN_A
H. Lundbeck A/s Class A — Lundbeck — Merger or Acquisition (October 2024)
15 slides from H. Lundbeck A/s Class A's merger presentation, Oct 14, 2024
Slide 1: Acquisition of Longboard Pharmaceuticals
Acquisition of Longboard Pharmaceuticals A significant step forward on our journey of being a focused innovator October 14, 2024 Martha, living with depression
Slide 2: Safe Harbor/Forward-Looking Statements
Safe Harbor/Forward-Looking Statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Forward looking statements include, without limitation, any stateme
Slide 3: Important Information for Investors and Security Holders
IMPORTANT INFORMATION FOR INVESTORS AND SECURITY HOLDERS The tender offer (the Offer) for the outstanding common stock of Longboard referred to in this presentation has not yet commenced. The description contained in this presentation is neither an offer to purchase nor a solicitation of an offer to
Slide 4: Lundbeck to acquire Longboard Pharmaceuticals
Lundbeck to acquire Longboard Pharmaceuticals Focused innovator strategy in action A significant step forward in Lundbeck’s Focused Innovator strategy Advancing our goal of building a robust neuro-rare franchise as an important addition to the amlenetug program The lead asset, bexicaserin, is target
Slide 5: A significant step forward in our Focused Innovator strategy
A significant step forward in our Focused Innovator strategy Driving long-term sustainable growth Secure mid-term growth Growth Focus on growth potential of key strategic brands to offset mid-term loss of exclusivities Lead with focused innovation Innovation Building a pipeline as the engine to fuel
Slide 6: Strengthening Lundbeck's leadership in neuroscience
Strengthening Lundbeck’s leadership in neuroscience Acquisition of Longboard supports long-term sustainable growth ambitions with a phase III asset Bexicaserin A selective 5-HT2C agonist with broad potential In development for Dravet syndrome, Lennox-Gastaut syndrome and other rare developmental epi
Slide 7: Ideal strategic fit illustrates focused innovator approach
Ideal strategic fit illustrates focused innovator approach Complementing neuro-rare franchise and building on experience in rare epilepsies Compelling efficacy profile in rare epilepsy supported by phase II data De-risked asset with several potential indications IP protection to 2041 Builds on Lundb
Slide 8: Building key position in neuro-rare
Building key position in neuro-rare Low complexity of integration of Longboard Asset Bexicaserin Longboard Pharmaceuticals, La Jolla Mode of action 5-HT2C agonist Indication DEEs and other refractory epilepsies • Founded in 2020 by Arena Pharmaceuticals, Inc. Phase III initiated (later acquired by P
Slide 9: Strong unmet need across broad range of indications
Strong unmet need across broad range of indications Insufficient treatment options available for epilepsy patients with drug-resistant seizures Epilepsy populations Classifying drug-resistant seizures DEEs are underserved Unmet needs remain DEEs are classified by type of seizure Only four with appro
Slide 10: Majority of DEEs have no approved treatment options
Majority of DEEs have no approved treatment options U.S. patient population of approximately 220,000 and half not served by licensed therapies Sizable opportunities across all DEEs 50.000 48.000 Main DEEs Approximately 120,000 patients 28.400 26.000 21.000 20.000 12.500 10.000 Other DEEs Approximate
Slide 11: Bexicaserin in phase III backed by strong clinical data
Bexicaserin in phase III backed by strong clinical data A differentiated, highly selective 5-HT2C agonist with a compelling efficacy profile Pre-clinical evidence • Reduced seizure, epileptiform activity, duration and number of epileptiform events in fish and rodent models Phase I – Healthy voluntee
Slide 12: Promising efficacy across multiple DEE sub-populations
Promising efficacy across multiple DEE sub-populations Phase II study showed Best-in-Class potential Bexicaserin reduced Clinical evidence from DEE sub-populations median countable motor seizures Reduction in median countable motor seizures Median percent change from baseline Bexicaserin 74.6% Place
Slide 13: Transformative and value-creating acquisition
Transformative and value-creating acquisition USD 2.5bn transaction to support long term sustainable growth ambitions Transaction details Deep value Financial impact Capital allocation • Purchase price: USD • De-risked asset with • Closing expected Dec. 2024 • No change to capital 60/share phase II
Slide 14: Acquisition reinforces strong position in neuroscience
Acquisition reinforces strong position in neuroscience Focused Innovator strategy in action Longboard fits perfectly with Lundbeck’s Focused Innovator strategy Addition of scientifically de-risked late-stage asset with several indication opportunities Forming an anchor asset in Lundbeck’s neuro-rare
Slide 15: Slide 15